Last reviewed · How we verify
Sambucol
Sambucol, marketed by Hadassah Medical Organization, holds a position in the consumer health market with its key composition patent set to expire in 2028. The product's primary strength lies in its established market presence and brand recognition. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Sambucol |
|---|---|
| Sponsor | Hadassah Medical Organization |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- BERRY- a Study of Sambucol ® in the Treatment, and Reduction of Symptoms in Participants With Coronavirus 19 (NA)
- Evaluating The Safety And Clinical Efficacy Of Elderberry Extract In Patients With Influenza (PHASE4)
- Efficacy of Sambucol in the Treatment of Influenza (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sambucol CI brief — competitive landscape report
- Sambucol updates RSS · CI watch RSS
- Hadassah Medical Organization portfolio CI